NASDAQ:NTRB Nutriband Q1 2026 Earnings Report $3.65 +0.07 (+1.96%) As of 12:05 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Nutriband EPS ResultsActual EPS-$0.12Consensus EPS -$0.13Beat/MissBeat by +$0.01One Year Ago EPSN/ANutriband Revenue ResultsActual Revenue$0.67 millionExpected Revenue$0.71 millionBeat/MissMissed by -$40.00 thousandYoY Revenue GrowthN/ANutriband Announcement DetailsQuarterQ1 2026Date5/30/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Nutriband Earnings HeadlinesNutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM ConferenceMay 15, 2026 | globenewswire.comNutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel PodcastApril 22, 2026 | globenewswire.comJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before major runs - says the window to get in early is closing fast. Brown is showing investors how to claim a stake in Elon Musk's company before it hits the public markets. Once the IPO happens, this pre-public opportunity disappears.June 8 at 1:00 AM | Brownstone Research (Ad)Nutriband Advances Lead Abuse-Deterrent Fentanyl Patch BrandingApril 7, 2026 | tipranks.comNutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl PatchMarch 30, 2026 | globenewswire.comNutriband AI Kinesiology Tapes approved for Distribution and Sale in Costa RicaMarch 18, 2026 | finance.yahoo.comSee More Nutriband Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nutriband? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nutriband and other key companies, straight to your email. Email Address About NutribandNutriband (NASDAQ:NTRB) develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.View Nutriband ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles These 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?Planet Labs: Coming Back Down to EarthDocusign: Another Beat, Another Selloff—Why the Analysts Are WrongA Lulu of a Miss Sends Lululemon to New Lows—Look Out BelowWhat's Make of Macy's: Berkshire Hathaway's Latest BuyFive Below Down 12% Post Earnings—Is the Selloff Overdone? Upcoming Earnings Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
